ketamine + amitriptyline + lidocaine

ketamine + amitriptyline + lidocaine (KeAmLi) is a topical compounded formulation developed for the treatment of chronic pruritus, particularly neurogenic and neuropathic forms such as brachioradial pruritus. The formulation typically contains 10% ketamine, 5% amitriptyline, and 5% lidocaine in a Lipoderm transdermal cream base. Its mechanism of action is multi-modal: ketamine acts as an N-methyl-D-aspartate (NMDA) receptor antagonist to mitigate central sensitization; lidocaine and amitriptyline function as voltage-gated sodium channel blockers to inhibit peripheral nerve transmission; and amitriptyline provides additional antipruritic effects through histamine H1 receptor antagonism and modulation of monoamine transporters. This combination therapy has been evaluated in Phase 2 clinical trials led by Dr. Gil Yosipovitch at the University of Miami to assess its efficacy against non-histaminergic itch provocations.

Other names

Lipoderm-Gil Yosipovitch-pruritusTopical Ketamine, Amitriptyline, and Lidocaine